company background image
NAVB logo

Navidea Biopharmaceuticals OTCPK:NAVB Stock Report

Last Price

US$0.036

Market Cap

US$4.3m

7D

-9.8%

1Y

-87.1%

Updated

26 Mar, 2024

Data

Company Financials

Navidea Biopharmaceuticals, Inc.

OTCPK:NAVB Stock Report

Market Cap: US$4.3m

NAVB Stock Overview

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics.

NAVB fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance0/6
Financial Health2/6
Dividends0/6

Navidea Biopharmaceuticals, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for Navidea Biopharmaceuticals
Historical stock prices
Current Share PriceUS$0.036
52 Week HighUS$0.33
52 Week LowUS$0.021
Beta1.13
1 Month Change-19.78%
3 Month Change-36.67%
1 Year Change-87.11%
3 Year Change-98.20%
5 Year Change-98.71%
Change since IPO-99.97%

Recent News & Updates

Recent updates

Need To Know: Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) Insiders Have Been Buying Shares

Feb 10
Need To Know: Navidea Biopharmaceuticals, Inc. (NYSEMKT:NAVB) Insiders Have Been Buying Shares

Shareholder Returns

NAVBUS BiotechsUS Market
7D-9.8%-0.5%0.6%
1Y-87.1%9.6%29.5%

Return vs Industry: NAVB underperformed the US Biotechs industry which returned 10.2% over the past year.

Return vs Market: NAVB underperformed the US Market which returned 29.8% over the past year.

Price Volatility

Is NAVB's price volatile compared to industry and market?
NAVB volatility
NAVB Average Weekly Movement22.1%
Biotechs Industry Average Movement11.5%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: NAVB's share price has been volatile over the past 3 months.

Volatility Over Time: NAVB's weekly volatility (22%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
198313n/ahttps://www.navidea.com

Navidea Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of precision immunodiagnostic agents and immunotherapeutics. It operates in two segments, Diagnostic Substances and Therapeutic Development Programs. The company develops Manocept platform to target the CD206 mannose receptor expressed on activated macrophages for a range of diagnostic modalities, including single photon emission computed tomography, positron emission tomography (PET), gamma-scanning, and intra-operative and/or optical-fluorescence detection, as well as delivery of therapeutic compounds that target macrophages, and immune-and inflammation-involved diseases.

Navidea Biopharmaceuticals, Inc. Fundamentals Summary

How do Navidea Biopharmaceuticals's earnings and revenue compare to its market cap?
NAVB fundamental statistics
Market capUS$4.30m
Earnings (TTM)-US$8.81m
Revenue (TTM)US$610.00

5,918x

P/S Ratio

-0.4x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
NAVB income statement (TTM)
RevenueUS$610.00
Cost of RevenueUS$50.04k
Gross Profit-US$49.43k
Other ExpensesUS$8.77m
Earnings-US$8.81m

Last Reported Earnings

Sep 30, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.088
Gross Margin-8,102.62%
Net Profit Margin-1,444,993.44%
Debt/Equity Ratio-41.9%

How did NAVB perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.